No Data
No Data
Positive Earnings Growth Hasn't Been Enough to Get Haemonetics (NYSE:HAE) Shareholders a Favorable Return Over the Last Five Years
How Do Investors Really Feel About Haemonetics?
Vivasure Medical Announces European CE Mark Approval Of PerQseal Elite Vascular Closure System
Highland Arms Enterprises Acquires Camprendy
Express News | Haemonetics Corp : Citigroup Cuts Target Price to $71 From $72
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 49% Undervalued